Get a full analysis report for any ticker →

SECTOR COVERAGE

Healthcare & Biotech Stock News

42 STORIES · UPDATED YESTERDAY

Healthcare pairs durable cash flows with binary catalyst risk. We cover drug approvals, pipeline read-outs, and payer dynamics across pharma, med-tech, and providers — separating a real clinical inflection from a press-release pop.

By Basis Report Editorial DeskReviewed by Basis Report Methodology TeamMethodology
Top StoryTHC

Tenet Healthcare Tops Q3 2026 With $2 Billion Free Cash Flow

Tenet Healthcare beat Q3 2026 earnings expectations, generating $2.0bn in free cash flow on $22.2bn in trailing revenue while the forward multiple prices in an EPS decline that has not yet appeared in the reported numbers.

THCAnalysis

Tenet's 43% Earnings Surprise Didn't Stop Insider Selling

Tenet Healthcare beat Q2 earnings by 43.6%, its fourth consecutive quarterly surprise, with free cash flow reaching $2.25 billion. CEO and other insid…

SLSAnalysis

SELLAS CEO Claims GPS Has 'Very Good Chance' to Beat AML

CEO Angelos Stergiou has stated GPS has a "very good chance" to beat prior survival outcomes, with SELLAS's $2.42 billion valuation staked almost enti…

PRAXAnalysis

Praxis Jumps on FDA Bets as UBS Targets $706, 171% Upside

Praxis Precision Medicines has a $7.26 billion market cap despite zero revenue, supported by two pending FDA verdicts for ulixacaltamide and relutrigi…

SMMTAnalysis

Summit Therapeutics Trades Below AstraZeneca's $18.36

AstraZeneca's $2 billion investment in Summit Therapeutics at $18.36 per share is now worth less on paper, with the stock trading at $14.63 as 26.3% s…

RDYAnalysis

Dr. Reddy's 200-Day Breakout Faces FDA Visakhapatnam Risk

Dr. Reddy's Laboratories crossed above its 200-day moving average this week, a technical milestone that coincided with FDA pre-approval inspection obs…

ARWRAnalysis

Arrowhead Insiders Sold at $87; UBS Now Targets $109

Arrowhead Pharmaceuticals' interim Alzheimer's data showed 73% mean CSF tau reduction at Day 105, prompting UBS to raise its price target to $109 on O…

RDYAnalysis

Dr. Reddy's Faces FDA Flags Ahead of Friday Earnings

Dr. Reddy's received FDA pre-approval inspection observations at two manufacturing sites just days after rallying past its 200-day moving average. Wit…

NAMSAnalysis

NAMS CEO Buys As CSO Cashes Out Before PREVAIL Risk

NewAmsterdam Pharma's CEO made the only open-market insider purchase in three months while his Chief Scientific Officer sold $4.6 million in the same …

HIMSBrief-14%

Hims & Hers Health Drops 14% on Securities Fraud Lawsuit

Hims & Hers Health fell over 14% after Kahn Swick & Foti filed a securities fraud class action alleging deceptive billing and privacy practices, with …

THCBrief

Tenet Healthcare Extends $2 Billion in Debt to 2034, Cuts Risk

Tenet Healthcare refinanced $2.0bn of debt, extending maturities to 2034 and removing near-term default risk, while shifting investor focus to whether…

HIMSAnalysis

HIMS Rally Hides Insider Selling After Record EPS Misses

HIMS stock hit a 2026 high after securing a $400 million JPMorgan working capital facility, yet five C-suite executives unloaded $3.61 million in shar…

PRAXAnalysis-12%

PRAX Falls 12% After Trial Setback Following Analyst Boost

Praxis Precision Medicines dropped 12% after-hours following a trial setback, just three days after analysts issued upgrades projecting 91% upside. Wi…

NAMSAnalysis

NAMS CSO Sold $3.4M Before Phase 3 Data Readout

NewAmsterdam Pharma's Chief Scientific Officer sold $3.4M worth of shares on August 24, immediately before the company's Phase 3 Obicetrapib data read…

ARWRAnalysis

Arrowhead's 750-Patient Heart Data: A $12B Test

Arrowhead Pharmaceuticals carries a $12 billion market cap sustained entirely by episodic milestone payments from GSK, Takeda, Amgen, and Sarepta, wit…

ARWRAnalysis

Arrowhead Directors Sell $1.19M Ahead of Key Heart Data

Two Arrowhead Pharmaceuticals directors sold a combined $1.19 million in shares on August 18, days before a 750-patient cardiovascular dataset is due …

DGXAnalysis

Quest Diagnostics Adds Alzheimer's Test After CEO Exit

Quest Diagnostics is adding Roche's FDA-cleared Alzheimer's blood test to its menu as the stock trades 25% above the price where the CEO sold shares s…

NAMSAnalysis

NewAmsterdam Pharma: CAO Sold $6.7M, Stock Below Floor.

NewAmsterdam Pharma's CAO sold $6.71 million in shares across three months at prices between $29.96 and $35.69, and the stock now trades at $27.79, be…

IONSAnalysis

Ionis Insiders Sold at $85, Then Bought at $52

Goldman Sachs raised its Ionis Pharmaceuticals price target today, lifting shares 4% in after-hours trading, yet the stock sits roughly 28% below the …

AMLXAnalysis

Amylyx Files Offering Same Day as Phase 3 Win

Amylyx Pharmaceuticals surged 45% after Avexitide posted positive Phase 3 results for post-bariatric hypoglycemia and congenital hyperinsulinism, cond…

AMLXBrief+45%

Amylyx Pharmaceuticals Jumps 45% as Trial Cuts Hypoglycemia by 55%

Amylyx Pharmaceuticals surged 45% in a single trading session after its experimental drug showed a 55% reduction in dangerous hypoglycemia events, a c…

HIMSBrief

Hims & Hers Health Tumbles on Q2 Miss With 31.9% Float Short

Hims & Hers Health missed Q2 bottom-line consensus estimates as losses widened more than expected, sending shares lower despite a guidance raise for t…

PRAXAnalysis

Praxis Jumps on FDA Checks, Vormatrigine Misses Phase 3

Praxis Precision Medicines jumped 15.95% on August 6 after FDA mid-cycle reviews flagged no significant efficacy issues and clinical site inspections …

TEMAnalysis

Tempus AI CEO Sells $7.7M After Material Agreement

Tempus AI CEO Eric Lefkofsky and four other executives sold a combined $10.3 million in shares during May 2026, following a Material Definitive Agreem…

ALHCAnalysis

ALHC Insiders Sell $24M as Stock Slides After Earnings

Alignment Healthcare beat earnings estimates in consecutive quarters and turned profitable, but the stock fell 19% as the market apparently priced in …

APLSAnalysis

Biogen Closes $5.6B Apellis Acquisition, APLS Delisted

Biogen completed its $5.6 billion acquisition of Apellis Pharmaceuticals on May 14, 2026, paying $41.00 per share in cash plus a contingent value righ…

OGNBrief

Organon Gets 24% Sun Pharma Buyout Bid at $13.25 Floor Price

Sun Pharma's all-cash offer for Organon at a 24% premium converts the stock from a fundamentals story into a merger arbitrage trade.

CPRXBrief

Catalyst Pharmaceuticals Pops on Angelini Takeover Talk, Target Lifted to $32

Catalyst Pharmaceuticals shares jumped on reports of acquisition interest from Italy's Angelini Pharma, with one analyst lifting the price target to $…

MOHBrief+14%

Molina Healthcare Stock Jumps 14% as Lower Medical Costs Overshadow $93M Charge

Molina Healthcare stock surged 14% after Q1 2026 earnings beat estimates on lower-than-expected medical costs, with the market ignoring a $93M impairm…

NKTRBrief

Nektar Therapeutics Raises $250 Million After Alopecia Drug Sends Stock Up 18%

Nektar Therapeutics is raising $250 million in a public stock offering timed to an 18.3% rally on positive alopecia trial data, a classic biotech move…

LEGNBrief+18%

Legend Biotech Surges 18% After Eli Lilly Strikes $7 Billion Cancer Therapy Deal

Eli Lilly struck a ~$7 billion deal tied to Legend Biotech's CARVYKTI cancer therapy, sending LEGN shares up as much as 18% for the stock's best sessi…

KLRABrief

Kailera Therapeutics Raises $625 Million in Biotech's Biggest IPO, Then Pops 63%

Kailera Therapeutics priced one of biotech's largest-ever IPOs at $625 million and saw shares surge roughly 63% on their first day, reflecting intense…

TVTXBrief+33%

Travere Therapeutics Surges 33% After FDA Approves the Only Drug for Rare Kidney Disease

Travere Therapeutics stock surged after FILSPARI became the first and only FDA-approved treatment for focal segmental glomerulosclerosis, a rare kidne…

TLXBrief

Telix Pharmaceuticals Jumps After FDA Accepts Brain Cancer Drug Filing

FDA accepted Telix Pharmaceuticals' NDA filing for its brain cancer imaging agent Pixclara, setting up a binary approval catalyst for the $804mn-reven…

ALHCBrief+16%

Alignment Healthcare Jumps 16% After Medicare Pays More Than Wall Street Expected

Alignment Healthcare surged 16% after CMS announced higher-than-expected 2026 Medicare Advantage reimbursement rates, boosting the outlook for a compa…

KODBrief

Kodiak Sciences Aces Second Phase 3 Trial for Zenkuda in Diabetic Retinopathy

Kodiak Sciences reported positive GLOW2 Phase 3 results showing Zenkuda achieved a 62.5% response rate vs 3.3% for sham in diabetic retinopathy, givin…

CNTABrief

Eli Lilly to Buy Centessa Pharmaceuticals for Up to $7.8bn in Neuro Push

Eli Lilly announced a deal to acquire Centessa Pharmaceuticals for up to $7.8bn, paying $6.3bn upfront to secure the biotech's orexin receptor pipelin…

APLSBrief

Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion

Biogen agreed to acquire Apellis Pharmaceuticals for $5.6bn in cash plus potential milestone payments, sending APLS shares up more than 100% as the de…

GRDNBrief+9.1%

Jefferies Initiates GRDN at Buy With $44 Target, Stock Surges 9.1%

Jefferies initiated Guardian Pharmacy Services (GRDN) at Buy with a $44 price target Monday, sparking a 9.1% single-day rally and establishing institu…

KODAnalysis

Kodiak Sciences Needs Second Phase 3 Trial Despite "Superiority" Claims

Kodiak Sciences announced positive GLOW2 Phase 3 results for tarcocimab tedromer, but the need for a second confirmatory study suggests regulatory com…

AAPGAnalysis

Ascentage Pharma's Protein Degrader Pivot Signals Traditional Pipeline Crisis

Ascentage Pharma received China IND clearance for BTK protein degrader APG-3288, marking a strategic shift into unproven PROTAC technology. The pivot …

NNNNAnalysis

Anbio Biotechnology Management Disclosure Gap Signals Coverage Blind Spot

Anbio Biotechnology operates with minimal public disclosure, creating an information asymmetry that sophisticated investors can exploit. The company's…

Keep going

Sample Reports
See a full teardown end to end — DCF, earnings-quality score, and red flags on AAPL, NVDA, MSFT and more.
Browse the reports →
Free Tools
193 calculators — DCF, earnings-quality scorer, capital-allocation grader. No signup, no card.
Open the tools →
The Field Guide
50 plain-English chapters on valuation and earnings quality — how to read a filing the way we do.
Start reading →

Your move

Run this same teardown on a stock you actually own.

Drop in any ticker and get an institutional-grade report in about 60 seconds — the full DCF, an earnings-quality score, and the red flags buried deep in the filing. No signup, no card.

Run a free report →
  • DCF valuation with bull & bear cases
  • Earnings-quality score from 0–100
  • Red-flag scan across the 10-K
  • Peer multiples & a fair-value range